Since the demand for protein production services has been increasing every year, some surveys show that the global market will observe a significant rise in the future. Protein expression’s market might grow from $1.7 billion in the year 2017 to $3.0 billion by the start of 2022. This can take place at a CAGR of 11.2% from the year 2017 through 2022.
If you are not aware of the expression market of protein, know that it has many types of segments available. These types are mammalian cell expression systems, prokaryotic expression systems, yeast expression systems, insect cell expression systems, algal-based expression systems, and cell-free expression systems. Furthermore, you might come across many of its extended segments that are based on services and products. They are streamlined into expression vectors, reagents, instruments, competent cells, and services. If you dismember the regions where such a service is comprehended, you will come across areas like Europe, Asia-Pacific, North America, and R.O.W. (Rest of the World).
Amid this COVID crisis, several companies have enrolled in this article, whose data defines the structure of protein production service. These organization profiles include Merck KGaA, Thermo Fisher Scientific Inc., Agilent Technologies, Promega Corp., Takara Holdings Inc., GenScript, Qiagen N.V., Bio-Rad Laboratories Inc., Lonza, and several others.
What is protein expression?
It is one of the techniques in which three methods – transcription, translation, and posttranslational modification happen to play a crucial role in many applications. This includes therapeutic protein production, biologics production, and some of the research applications. Furthermore, methods of recombinant protein expression have three types- in vitro protein expression, Vivo protein expression, and the crucial chemical protein synthesis. Another notable fact is that it is essential to have a variety of tools used for expression purposes. This process ensures the target protein’s successful expression.
Proteins can be regulated, synthesized, and modified into various living organisms based on their functional requirement in the host cell. That is because such proteins require a designated environment that is intracellular. It allows proteins to achieve the necessary tertiary and secondary structures. Some of the proteins also need post-insertion or translational modifications. Independently, this takes place in a cellular membrane to undergo protein’s proper functioning. Besides, some of the proteins’ production can also be a little harmful. But, that is for the host’s well-being. Thereby, it is essential to believe that there’s hardly any successful production method of recombinant proteins’ various types.
Why is there a high demand?
The high demand is a result of various perspectives and outcomes that take place in a market. Since the current pandemic has affected more or less every aspect of such a service, there are multiple aspects through which we can analyze its present situation. Applications and products are two of the most critical factors that determine success in the market. But, in proteins’ case, the success rate relies on the chronic diseases’ treatments. You can categorize the protein expression market into six types: mammalian cell expression system, prokaryotic expression system, yeast cell expression system, insect cell expression system, algal-based expression system, and cell-free expression system.
Moreover, if you are not aware of this, know that the prokaryotic expression system-generated substantial revenue in the year 2016. Some experts have projected that the recombinant protein’s global market can expand with an average CAGR during the forecast period between 2017 and 2022. The growth estimates around US$ 460 million in revenue by the end of 2022.
As already discusses, the market has a share across every possible continent. However, North America had a significant market share of the recombinant protein market in the year and seemed to grow extensively during the analysis period. And, it might reach around US$ 150 million by the end of 2022. In the forecast period, Europe has also passed the estimation of growth and sits as a second-most position.
Europe is estimated to be the second most advantageous market for the recombinant protein. Moreover, the Middle East & Africa’s market can experience a quiet expansion through the year 2022. Recombinant proteins are a subject of discussion for the current market and shall continue to grow amid standard research activities. The revenues made from recombinant proteins are also expected to be around US$ 270 million by the end of 2022. Toxicity screening and Drug development and discovery have estimated to emerge as one of the fastest-growing applications in the field of recombinant proteins.
Some of the leading players of the recombinant protein market globally are A.M.S. Biotechnology (Europe) Limited, Abcam plc, BPS Bioscience Inc., Bio-Rad Laboratories, Inc., Crown Bioscience, Inc., PerkinElmer, Inc., Merck Millipore Limited, GenScript Corporation, Thermo Fisher Scientific, Inc, and Sigma Aldrich.